title: High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
abstract: OBJECTIVE
  Investigation of high-dose chemotherapy (HD-CT) followed by autologous hematopoietic stem-cell support compared with standard-dose chemotherapy (SD-CT) as adjuvant treatment in patients with primary breast cancer and 10 or more positive axillary lymph nodes.
  
  
  METHODS
  Between November 1993 and September 2000, 307 patients were randomized to receive (following four cycles of epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2), intravenously every 21 days) either HD-CT of cyclophosphamide 1500 mg/m(2), thiotepa 150 mg/m(2), and mitoxantrone 10 mg/m(2), intravenously for 4 consecutive days followed by stem-cell support; or SD-CT in three cycles of cyclophosphamide 500 mg/m(2), methotrexate 40 mg/m(2), and fluorouracil 600 mg/m(2) intravenously on days 1 and 8, every 28 days. The primary end point was event-free survival.
  
  
  RESULTS
  After a median follow-up of 3.8 years, 144 events with respect to event-free survival have been observed (HD-CT: 63 events; SD-CT: 81 events). The first event of failure (HD-CT v SD-CT) was an isolated locoregional recurrence (nine v 11), a distant failure (52 v 68), and death without recurrence (two v two). The estimated relative risk of HD-CT versus SD-CT was 0.75 (95% CI, 0.54 to 1.06; P =.095). Overall survival showed no difference (HD-CT: 40 deaths; SD-CT: 49 deaths).
  
  
  CONCLUSIONS
  There was a trend in favor of HD-CT with respect to event-free survival, but without statistical significance. Further follow-up and a meta-analysis of all randomized studies will reveal the effect of HD-CT as compared with SD-CT as adjuvant treatment in high-risk primary breast cancer.
authors.affiliation: Transplant Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. zander@uke.uni-hamburg.de
authors.forename: A R
authors.initials: AR
authors.lastname: Zander
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: C
authors.initials: C
authors.lastname: Schmoor
authors.forename: W
authors.initials: W
authors.lastname: Krüger
authors.forename: V
authors.initials: V
authors.lastname: Möbus
authors.forename: N
authors.initials: N
authors.lastname: Frickhofen
authors.forename: B
authors.initials: B
authors.lastname: Metzner
authors.forename: W
authors.initials: W
authors.lastname: Schultze
authors.forename: W E
authors.initials: WE
authors.lastname: Berdel
authors.forename: M
authors.initials: M
authors.lastname: Koenigsmann
authors.forename: E
authors.initials: E
authors.lastname: Thiel
authors.forename: H
authors.initials: H
authors.lastname: Wandt
authors.forename: K
authors.initials: K
authors.lastname: Possinger
authors.forename: L
authors.initials: L
authors.lastname: Trümper
authors.forename: R
authors.initials: R
authors.lastname: Kreienberg
authors.forename: M
authors.initials: M
authors.lastname: Carstensen
authors.forename: E H
authors.initials: EH
authors.lastname: Schmidt
authors.forename: F
authors.initials: F
authors.lastname: Jänicke
authors.forename: M
authors.initials: M
authors.lastname: Schumacher
authors.forename: W
authors.initials: W
authors.lastname: Jonat
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D014182:Transplantation, Autologous